1 |
Chalasani NP, Hayashi PH, Bonkovsky HL, Navarro VJ, Lee WM, Fontana RJ, et al. ACG clinical guideline: the diagnosis and management of idiosyncratic drug-induced liver injury. Am J Gastroenterol 2014;109:950-66.
DOI
|
2 |
Yu YC, Mao YM, Chen CW, Chen JJ, Chen J, Cong WM, et al. CSH guidelines for the diagnosis and treatment of drug-induced liver injury. Hepatol Int 2017;11:221-41.
DOI
|
3 |
European Association for the Study of the Liver. EASL clinical practice guidelines: drug-induced liver injury. J Hepatol 2019; 70:1222-61.
DOI
|
4 |
Fontana RJ, Seeff LB, Andrade RJ, Bjornsson E, Day CP, Serrano J, et al. Standardization of nomenclature and causality assessment in drug-induced liver injury: summary of a clinical research workshop. Hepatology 2010;52:730-42.
DOI
|
5 |
Devarbhavi H. An update on drug-induced liver injury. J Clin Exp Hepatol 2012;2:247-59.
DOI
|
6 |
Benichou C. Criteria of drug-induced liver disorders. Report of an international consensus meeting. J Hepatol 1990;11:272-6.
DOI
|
7 |
Visentin M, Lenggenhager D, Gai Z, Kullak-Ublick GA. Drug-induced bile duct injury. Biochim Biophys Acta Mol Basis Dis 2018;1864:1498-506.
DOI
|
8 |
Wang T, Zhao X, Shao C, Ye L, Guo J, Peng N, et al. A proposed pathologic sub-classification of drug-induced liver injury. Hepatol Int 2019;13:339-51.
DOI
|
9 |
Ahmad J, Odin JA. Epidemiology and genetic risk factors of drug hepatotoxicity. Clin Liver Dis 2017;21:55-72.
DOI
|
10 |
Holt MP, Ju C. Mechanisms of drug-induced liver injury. AAPS J 2006;8:E48-54.
DOI
|
11 |
Bell LN, Chalasani N. Epidemiology of idiosyncratic drug-induced liver injury. Semin Liver Dis 2009;29:337-47.
DOI
|
12 |
Hoofnagle JH. Drug-induced liver injury network (DILIN). Hepatology 2004;40:773.
DOI
|
13 |
Suk KT, Kim DJ, Kim CH, Park SH, Yoon JH, Kim YS, et al. A prospective nationwide study of drug-induced liver injury in Korea. Am J Gastroenterol 2012;107:1380-7.
DOI
|
14 |
Danan G, Benichou C. Causality assessment of adverse reactions to drugs--I. A novel method based on the conclusions of international consensus meetings: application to drug-induced liver injuries. J Clin Epidemiol 1993;46:1323-30.
DOI
|
15 |
Hayashi PH. Overview of causality assessment in drug-induced liver injury. Clin Liver Dis (Hoboken) 2017;9:29-33.
DOI
|
16 |
Neuman MG. Biomarkers of drug-induced liver toxicity. Ther Drug Monit 2019;41:227-34.
DOI
|
17 |
Hayashi PH. Drug-induced liver injury network causality assessment: criteria and experience in the United States. Int J Mol Sci 2016;17:201.
DOI
|
18 |
Antoine DJ, Williams DP, Kipar A, Jenkins RE, Regan SL, Sathish JG, et al. High-mobility group box-1 protein and keratin-18, circulating serum proteins informative of acetaminophen-induced necrosis and apoptosis in vivo. Toxicol Sci 2009;112:521-31.
DOI
|
19 |
McGill MR, Jaeschke H. Biomarkers of drug-induced liver injury. Adv Pharmacol 2019;85:221-39.
DOI
|
20 |
Lammert C, Einarsson S, Saha C, Niklasson A, Bjornsson E, Chalasani N. Relationship between daily dose of oral medications and idiosyncratic drug-induced liver injury: search for signals. Hepatology 2008;47:2003-9.
DOI
|
21 |
Russmann S, Kullak-Ublick GA, Grattagliano I. Current concepts of mechanisms in drug-induced hepatotoxicity. Curr Med Chem 2009;16:3041-53.
DOI
|
22 |
Gijbels E, Vinken M. Mechanisms of drug-induced cholestasis. Methods Mol Biol 2019;1981:1-14.
DOI
|
23 |
Lee WJ, Kim HW, Lee HY, Son CG. Systematic review on herb-induced liver injury in Korea. Food Chem Toxicol 2015;84:47-54.
DOI
|
24 |
Chalasani N, Fontana RJ, Bonkovsky HL, Watkins PB, Davern T, Serrano J, et al. Causes, clinical features, and outcomes from a prospective study of drug-induced liver injury in the United States. Gastroenterology 2008;135:1924-34.
DOI
|
25 |
Hayashi PH, Bjornsson ES. Long-term outcomes after drug-induced liver injury. Curr Hepatol Rep 2018;17:292-9.
DOI
|
26 |
Zhu Y, Niu M, Chen J, Zou ZS, Ma ZJ, Liu SH, et al. Hepatobiliary and pancreatic: comparison between Chinese herbal medicine and Western medicine-induced liver injury of 1985 patients. J Gastroenterol Hepatol 2016;31:1476-82.
DOI
|
27 |
Wysowski DK, Swartz L. Adverse drug event surveillance and drug withdrawals in the United States, 1969-2002: the importance of reporting suspected reactions. Arch Intern Med 2005;165:1363-9.
DOI
|
28 |
Bjornsson ES. Epidemiology and risk factors for idiosyncratic drug-induced liver injury. Semin Liver Dis 2014;34:115-22.
DOI
|
29 |
Patel SJ, Milwid JM, King KR, Bohr S, Iracheta-Vellve A, Li M, et al. Gap junction inhibition prevents drug-induced liver toxicity and fulminant hepatic failure. Nat Biotechnol 2012;30:179-83.
DOI
|
30 |
Chalasani N, Bjornsson E. Risk factors for idiosyncratic drug-induced liver injury. Gastroenterology 2010;138:2246-59.
DOI
|
31 |
Li H, He J, Jia W. The influence of gut microbiota on drug metabolism and toxicity. Expert Opin Drug Metab Toxicol 2016; 12:31-40.
DOI
|
32 |
Teschke R, Danan G. Diagnosis and management of drug-induced liver injury (DILI) in patients with pre-existing liver disease. Drug Saf 2016;39:729-44.
DOI
|
33 |
Chalasani N, Regev A. Drug-induced liver injury in patients with preexisting chronic liver disease in drug development: how to identify and manage? Gastroenterology 2016;151:1046-51.
DOI
|
34 |
Zimmerman HJ. Hepatotoxicity: the adverse effects of drugs and other chemicals on the liver. 2nd ed. Philadelphia: Lippincott Williams & Wilkins; 1999.
|
35 |
Reuben A. Hy's law. Hepatology 2004;39:574-8.
DOI
|
36 |
Lo Re V 3rd, Haynes K, Forde KA, Goldberg DS, Lewis JD, Carbonari DM, et al. Risk of acute liver failure in patients with drug-induced liver injury: evaluation of Hy's law and a new prognostic model. Clin Gastroenterol Hepatol 2015;13:2360-8.
DOI
|
37 |
Robles-Diaz M, Lucena MI, Kaplowitz N, Stephens C, Medina-Caliz I, Gonzalez-Jimenez A, et al. Use of Hy's law and a new composite algorithm to predict acute liver failure in patients with drug-induced liver injury. Gastroenterology 2014;147:109-18.
DOI
|
38 |
de Boer YS, Sherker AH. Herbal and dietary supplement-induced liver injury. Clin Liver Dis 2017;21:135-49.
DOI
|
39 |
Teschke R, Wolff A, Frenzel C, Schwarzenboeck A, Schulze J, Eickhoff A. Drug and herb induced liver injury: Council for International Organizations of Medical Sciences scale for causality assessment. World J Hepatol 2014;6:17-32.
DOI
|
40 |
Garcia-Cortes M, Stephens C, Lucena MI, Fernandez-Castaner A, Andrade RJ. Causality assessment methods in drug induced liver injury: strengths and weaknesses. J Hepatol 2011;55:683-91.
DOI
|
41 |
Suh JI, Sakong JK, Lee K, Lee YK, Park JB, Kim DJ, et al. Anxiety and depression propensities in patients with acute toxic liver injury. World J Gastroenterol 2013;19:9069-76.
DOI
|
42 |
Ford R, Schwartz L, Dancey J, Dodd LE, Eisenhauer EA, Gwyther S, et al. Lessons learned from independent central review. Eur J Cancer 2009;45:268-74.
DOI
|
43 |
Lee WM, Hynan LS, Rossaro L, Fontana RJ, Stravitz RT, Larson AM, et al. Intravenous N-acetylcysteine improves transplant-free survival in early stage non-acetaminophen acute liver failure. Gastroenterology 2009;137:856-64.
DOI
|
44 |
Bateman DN, Dear JW, Thanacoody HK, Thomas SH, Eddleston M, Sandilands EA, et al. Reduction of adverse effects from intravenous acetylcysteine treatment for paracetamol poisoning: a randomised controlled trial. Lancet 2014;383:697-704.
DOI
|
45 |
Singh S, Hynan LS, Lee WM; Acute Liver Failure Study Group. Improvements in hepatic serological biomarkers are associated with clinical benefit of intravenous N-acetylcysteine in early stage non-acetaminophen acute liver failure. Dig Dis Sci 2013; 58:1397-402.
DOI
|
46 |
Hu PF, Xie WF. Corticosteroid therapy in drug-induced liver injury: pros and cons. J Dig Dis 2019;20:122-6.
DOI
|
47 |
O'Grady JG, Alexander GJ, Hayllar KM, Williams R. Early indicators of prognosis in fulminant hepatic failure. Gastroenterology 1989;97:439-45.
DOI
|
48 |
Hu PF, Wang PQ, Chen H, Hu XF, Xie QP, Shi J, et al. Beneficial effect of corticosteroids for patients with severe drug-induced liver injury. J Dig Dis 2016;17:618-27.
DOI
|
49 |
Reuben A, Koch DG, Lee WM; Acute Liver Failure Study Group. Drug-induced acute liver failure: results of a U.S. multicenter, prospective study. Hepatology 2010;52:2065-76.
DOI
|
50 |
Mindikoglu AL, Magder LS, Regev A. Outcome of liver transplantation for drug-induced acute liver failure in the United States: analysis of the United Network for Organ Sharing database. Liver Transpl 2009;15:719-29.
DOI
|
51 |
Rudraiah S, Zhang X, Wang L. Nuclear receptors as therapeutic targets in liver disease: are we there yet? Annu Rev Pharmacol Toxicol 2016;56:605-26.
DOI
|
52 |
Suh JI. Role of PXR and CAR in cholestasis. Korean J Hepatol 2006;12:5-15.
|
53 |
Zhang J, Huang W, Chua SS, Wei P, Moore DD. Modulation of acetaminophen-induced hepatotoxicity by the xenobiotic receptor CAR. Science 2002;298:422-4.
DOI
|
54 |
Cheng J, Ma X, Krausz KW, Idle JR, Gonzalez FJ. Rifampicin-activated human pregnane X receptor and CYP3A4 induction enhance acetaminophen-induced toxicity. Drug Metab Dispos 2009;37:1611-21.
DOI
|
55 |
Ni HM, Jaeschke H, Ding WX. Targeting autophagy for drug-induced hepatotoxicity. Autophagy 2012;8:709-10.
DOI
|
56 |
Fraser K, Bruckner DM, Dordick JS. Advancing predictive hepatotoxicity at the intersection of experimental, in silico, and artificial intelligence technologies. Chem Res Toxicol 2018;31: 412-30.
DOI
|
57 |
Huh D, Torisawa YS, Hamilton GA, Kim HJ, Ingber DE. Microengineered physiological biomimicry: organs-on-chips. Lab Chip 2012;12:2156-64.
DOI
|
58 |
Kimura H, Sakai Y, Fujii T. Organ/body-on-a-chip based on microfluidic technology for drug discovery. Drug Metab Pharmacokinet 2018;33:43-8.
DOI
|
59 |
Beckwitt CH, Clark AM, Wheeler S, Taylor DL, Stolz DB, Griffith L, et al. Liver 'organ on a chip'. Exp Cell Res 2018;363:15-25.
DOI
|
60 |
Xu Y, Dai Z, Chen F, Gao S, Pei J, Lai L. Deep learning for drug-induced liver injury. J Chem Inf Model 2015;55:2085-93.
DOI
|
61 |
Suh JI. Establishment of tertiary hospital including southeast clinical research center in the era of the 4th industrial revolution. In: Choi YJ, editor. The 58th annual meeting and international symposium of Korean Society of Life Science; 2017 Aug 3-4; Gyeongju, Korea. Busan: Korean Society of Life Science; 2017. p. 71.
|